Six trials with 415 patients (214 in the experimental group, 201 in the control group) were included.
Five trials (349 patient) had 12-month follow-up and 2 trials (136 patients) had 24-month follow-up.
Intention-to-treat analysis.
Low-dose neuroleptic therapy was not as effective as standard-dose in preventing relapse, pooled OR was 2.08 (95% confidence interval, CI: 1.3, 3.3, p<0.005) at 12 months and 1.09 (95% CI: 0.55, 2.1) at 24 months. The RR reduction was -47% (95% CI: -15, -88) at 12 months and -5% (95% CI: 28, -52) at 24 months.
Efficacy analysis.
Low-dose neuroleptic therapy was not as effective as standard-dose in preventing relapse, pooled OR was 2.60 (95% CI: 1.5, 4.4, p<0.001) at 12 months and 1.80 (95% CI: 0.83, 3.9) at 24 months. The RR reduction was -65% (95% CI: -25, -117) at 12 months and -52% (95% CI: 13, -167) at 24 months.